CD8A and cancer: NKTR-214 is designed to sustain growth and survival of specific cancer-killing T cells and NK ells that specifically recognize a tumor target by targeting tumor infiltrating cells lymphocytes by binding to the CD122 receptor expressed by effector CD8+ T cells and NK cells (Bentebibel et al., 2019).